Table 3. Univariate and multivariate analyses of risk factors for HBV reactivation in lymphoma patients with baseline HBV DNA≥2000 IU/mL.
| Parameters | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| P value | OR | 95% Confidence Interval | P value | ||
| Gender (Male) | 0.829 | - | - | - | - |
| Age(>60years) | 0.849 | - | - | - | - |
| Ann Arbor stage (Ⅲ~Ⅳ) | 0.815 | - | - | - | - |
| Liver involvement(+) | 1.000 | - | - | - | - |
| HBeAg positive a | 0.022 | 3.189 | 1.204 | 8.446 | 0.020 |
| Use of anthracyclines | 0.041 | 0.081 | |||
| Use of rituximab | 0.222 | - | - | - | - |
| Use of steroids | 0.052 | - | - | - | 0.106 |
| Hematopoietic stem cell transplantation | 0.099 | - | - | - | 0.109 |
| Use of lamivudine plus adefovir | 0.012 | 0.263 | 0.079 | 0.887 | 0.030 |
a Complete information on initial HBV status was available in 78 cases.
Abbreviations: HBV, hepatitis B virus.